- Home
- ASMB vs BIOA Comparison
ASMB vs BIOA Comparison
Compare ASMB & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- BIOA
- Stock Information
- Founded
- ASMB 2005
- BIOA 2015
- Country
- ASMB United States
- BIOA United States
- Employees
- ASMB N/A
- BIOA N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- BIOA Health Care
- Exchange
- ASMB Nasdaq
- BIOA Nasdaq
- Market Cap
- ASMB 130.2M
- BIOA 139.8M
- IPO Year
- ASMB 2010
- BIOA 2024
- Fundamental
- Price
- ASMB $17.31
- BIOA $4.28
- Analyst Decision
- ASMB Strong Buy
- BIOA Hold
- Analyst Count
- ASMB 3
- BIOA 4
- Target Price
- ASMB $33.00
- BIOA $5.67
- AVG Volume (30 Days)
- ASMB 32.4K
- BIOA 391.6K
- Earning Date
- ASMB 08-07-2025
- BIOA 08-15-2025
- Dividend Yield
- ASMB N/A
- BIOA N/A
- EPS Growth
- ASMB N/A
- BIOA N/A
- EPS
- ASMB N/A
- BIOA N/A
- Revenue
- ASMB $32,154,000.00
- BIOA $1,451,000.00
- Revenue This Year
- ASMB $0.04
- BIOA N/A
- Revenue Next Year
- ASMB N/A
- BIOA N/A
- P/E Ratio
- ASMB N/A
- BIOA N/A
- Revenue Growth
- ASMB 148.33
- BIOA N/A
- 52 Week Low
- ASMB $7.75
- BIOA $2.88
- 52 Week High
- ASMB $19.93
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- ASMB 68.78
- BIOA N/A
- Support Level
- ASMB $16.50
- BIOA N/A
- Resistance Level
- ASMB $17.94
- BIOA N/A
- Average True Range (ATR)
- ASMB 0.82
- BIOA 0.00
- MACD
- ASMB -0.07
- BIOA 0.00
- Stochastic Oscillator
- ASMB 73.75
- BIOA 0.00
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.